Ocular gene therapy specialist Pulsesight Therapeutics SAS has launched with seed funding and is raising a series A to take forward two programs using electroporation to deliver plasmid DNA in the treatment of wet age-related macular degeneration and geographic atrophy.
Continuing the spate of regulatory approvals for pulsed field ablation (PFA) devices around the world, Johnson & Johnson’s Biosense Webster Inc. unit secured CE mark for the Varipulse platform for treatment of symptomatic, drug-refractory recurrent paroxysmal atrial fibrillation.
Mainstay Medical Holdings plc raised $125 million in equity financing which it will use to conduct clinical trials and continue the commercial roll out of its Reactiv8 neurostimulation therapy that treats chronic lower back pain.
The COVID-19 pandemic is well known for increasing telehealth utilization, including remote patient monitoring, but there are still issues with payer coverage policies even a year after the formal end of the public health emergency for COVID.
Osang Healthcare Co. Ltd. is attempting a second listing on the Kosdaq market with an IPO, planned sometime in March, to fund the company’s growth beyond the COVID-19 pandemic.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Perimeter Medical Imaging AI, Trisalus Life Sciences.
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Aidoc, AMDI, Endologix, Medtronic, Ontrak, Spineart, Wheeler Bio.
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: AIOmega, Biosense Webster, Femasys, Nevro, Onward Medical, Vapotherm.
RSS
